J&J faces price and patent probe over TB drug in South Africa

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

J&J faces price and patent probe over TB drug in South Africa

Aerial view of Capetown, SOuth Africa
Cape Town

The drugmaker is reportedly accused of excessive pricing for anti-TB drug bedaquiline and patent evergreening

South Africa’s Competition Commission will investigate Johnson & Johnson over excessive pricing for a tuberculosis drug and patent evergreening, local media reported yesterday, September 14.

The US drugmaker has faced heavy criticism this year over its pricing and patent strategies for bedaquiline, which is used to treat drug-resistant TB.

South African officials are said to be concerned that South Africa is paying twice as much for the drug as other low- and middle-income countries.

The Health Justice Initiative (HJI), a non-profit organisation, announced the probe after a briefing from government officials.

A spokesperson for the Competition Commission confirmed the news to local media and said it would issue a full statement soon.

Bedaquiline prices fell this summer after J&J agreed to license patents to the Stop TB Partnership’s Global Drug Facility.

The Stop TB Partnership is a UN-backed organisation aimed at improving access to TB treatment.

That deal came after access to medicine campaigners targeted J&J over its efforts to extend patent protection on bedaquiline, which is set to expire in most countries this year.

Last month, the Stop TB Partnership revealed that prices for the drug fell by up to 55% as a result of the J&J licence.

J&J now charges most lower-income countries a headline price of $130 for a six-month course of the drug compared to the old figure of $289.

But South Africa doesn’t appear to be benefiting from the slide in prices.

Under the Ministry of Health’s latest deal with J&J, concluded last month, South Africa will pay R5,500 ($288.62) for a six-month course.

Fatima Hassan, a prominent health lawyer and founder of the HJI, called the news “unprecedented and welcome”.

“It is time our country stands up to the bullying of multinational pharmaceutical corporations, in all its forms,” she said.

A spokesperson for J&J said: the company had a "longstanding commitment" to South Africa’s fight against multidrug-resistant tuberculosis (MDR-TB).

"Today, all patients in South Africa who require bedaquiline, our medicine for MDR-TB, have access to it thanks to our collaboration with the government of South Africa and other stakeholders, which has contributed to a steady decline in TB incidence.

"The company will cooperate fully with the Competition Commission in its inquiry, and cannot comment further while this is ongoing," the spokesperson said.

more from across site and SHARED ros bottom lb

More from across our site

Exclusive data reveals law firms are failing to go above and beyond for their corporate clients, with in-house counsel saying advisers should consider more transparent billing processes
Arty Rajendra and Gary Moss discuss why ‘thorough and intense’ preparation, plus the odd glass of wine, led to a record FRAND victory for their client
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Managing IP gives a taster of the numbers behind this year’s IP STARS trademark rankings, and looks back at our 2025 award winners
Updates from IP offices, the shifting requirements of in-house counsel, and news of London 2026 were among major talking points on Sunday
Etienne Sanz de Acedo discusses the association’s three-year plan, what he is looking forward to in San Diego, and why London came calling for 2026
Professionals from three organisations reveal what led them to sponsor Brand Action and why doing so can build camaraderie
The results of a UK government consultation on the exhaustion of IP rights and an annual review published by the EPO’s Boards of Appeal were also among the top talking points this week
The decision disregards Perlmutter’s work at the US Copyright Office and comes at a time when strong leadership and expertise are crucial
Sources say the decision to fire Shira Perlmutter raises constitutional concerns and speculate on what the decision could mean for the country’s approach to AI
Gift this article